The economic cost of stroke-associated pneumonia in a UK setting. Issue 3 (3rd April 2018)

• Record Type: Journal Article
• Authors: Ali, A. N.; Howe, J.; Majid, A.; Redgrave, J.; Pownall, S.; Abdelhafiz, A. H.
• Is Part Of: Topics in stroke rehabilitation. Volume 25:Issue 3(2018)
• Page Start: 214
• Page End: 223
• Publication Date: 2018-04-03
• Subjects: Stroke -- pneumonia -- cost -- The UK; Cerebrovascular disease -- Patients -- Rehabilitation -- Periodicals; Cerebrovascular disease -- Periodicals; 616.810305
• DOI: 10.1080/10749357.2017.1398482
• Languages: English
• ISSNs: 1074-9357

Abstract

Abstract: Introduction: Stroke-associated pneumonia (SAP) is common, however, data on the economic impact of SAP are scarce. This study aimed to prospectively evaluate the impact of SAP on acute stroke care costs in a UK setting. Methods: Prospective cohort study of 213 consecutive patients with stroke (196 ischemic, 17 hemorrhagic) was admitted to a UK hospital over 1 year. Socio demographic and clinical characteristics were recorded along with all treatments and rehabilitation activity. Patients were classified as having SAP if they fulfilled criteria for "probable" or "definite" respiratory tract infection according to the Centres for Disease Control and Prevention definition, within the first seven days following stroke. Resource use was calculated using a "bottom up" approach of cumulative unit costs. Univariate and multivariate regression analyses were used to establish independent predictors of direct costs. Results: Probable or definite SAP occurred in 13.2% (28/213) of patients. Patients with SAP experienced greater inpatient stays (31 days vs. 9 days, p ≤ 0.001) and higher in-hospital mortality (29.2% vs. 10.2%, p = 0.007). Mean (SD) acute care costs per patient was £7035 (6767), but costs were significantly greater for patients with SAP than without [£14, 371 (9484) versus £6, 103 (5, 735); p ≤ 0.001]. SAP was an independent predictor of costs along with increasing stroke severity (NIHSS) and age. Occurrence of SAP resulted in an adjusted incremental additional cost of £5817 (95% CI 4945–6689; p = 0.001) per patient. Conclusions: SAP increased acute care costs for stroke by approximately 80%. This provides further impetus for research aimed at reducing SAP, and will inform cost-effectiveness analyses of potential therapeutic strategies.